OpenLB
Open Library of Bioscience
Advanced Search
Transplantation and cellular therapy
10, 2022;28 (10): 677.e1-677.e6.

Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantation in the Era of the COVID-19 Pandemic: An Update from the Japan Marrow Donor Program.

Yoshinobu Kanda, Noriko Doki, Minoru Kojima, Shinichi Kako, Masami Inoue, Naoyuki Uchida, Yasushi Onishi, Reiko Kamata, Mika Kotaki, Ryoji Kobayashi, Junji Tanaka, Takahiro Fukuda, Nobuharu Fujii, Koichi Miyamura, Shin-Ichiro Mori, Yasuo Mori, Yasuo Morishima, Hiromasa Yabe, Yoshiko Atsuta, Yoshihisa Kodera
Author Information
  1. Yoshinobu Kanda: Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan. Electronic address: ycanda-tky@umin.ac.jp.
  2. Noriko Doki: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  3. Minoru Kojima: Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  4. Shinichi Kako: Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
  5. Masami Inoue: Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  6. Naoyuki Uchida: Department of Hematology, Toranomon Hospital, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  7. Yasushi Onishi: Department of Hematology, Tohoku University Hospital, Sendai, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  8. Reiko Kamata: Nonprofit Organization Blood Disorder Information and Support Service "Tsubasa", Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  9. Mika Kotaki: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  10. Ryoji Kobayashi: Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  11. Junji Tanaka: Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  12. Takahiro Fukuda: Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  13. Nobuharu Fujii: Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  14. Koichi Miyamura: Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  15. Shin-Ichiro Mori: Hematology Department, St. Luke's International Hospital, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  16. Yasuo Mori: Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  17. Yasuo Morishima: Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  18. Hiromasa Yabe: Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  19. Yoshiko Atsuta: Japanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
  20. Yoshihisa Kodera: Aichi Medical University School of Medicine, Aichi, Japan.
PMID: 35803526 DOI: 10.1016/j.jtct.2022.06.022

Abstract

During the COVID-19 pandemic, donor grafts are frequently cryopreserved to ensure that a graft is available before starting a conditioning regimen. However, there have been conflicting reports on the effect of cryopreservation on transplantation outcomes. Also, the impact of cryopreservation may differ in bone marrow (BM) transplantation (BMT) and peripheral blood stem cell (PBSC) transplantation (PBSCT). In this retrospective study, we analyzed the clinical data of both cryopreserved unrelated BMTs (n = 235) and PBSCTs (n = 118) and compared these with data from a large control cohort without cryopreservation including 4133 BMTs and 720 PBSCTs. Among the patients with cryopreserved grafts, 10 BMT recipients (4.3%) and 3 PBSCT recipients (2.5%) did not achieve neutrophil engraftment after transplantation, including 4 of the former and all 3 of the latter who died early before engraftment. In a multivariate analysis, cryopreservation was not associated with neutrophil engraftment in BMT but significantly delayed neutrophil engraftment in PBSCT (hazard ratio [HR], .82; 95% confidence interval [CI], .69 to .97; P = .023). There was an interaction with borderline significance between cryopreservation and the stem cell source (P = .067). Platelet engraftment was delayed by cryopreservation after both BMT and PBSCT. Only 2 cryopreserved grafts (<1%) were unused during the study period. The cryopreservation of unrelated donor BM and PBSC grafts is associated with a slight delay in neutrophil and platelet engraftment but an acceptable rate of graft failure. PBSC grafts may be more sensitive to cryopreservation than BM grafts. Cryopreservation is a reasonable option during COVID-19 pandemic, provided that the apheresis and transplantation centers are adept at cryopreservation. © 2022 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

Keywords

Bone marrow transplantation COVID-19 Cryopreservation Japan Marrow Donor Program Peripheral blood stem cell transplantation

References

  1. Transplant Cell Ther. 2021 Dec;27(12):1022.e1-1022.e6 [PMID: 34571211]
  2. Bone Marrow Transplant. 1996 Feb;17(2):197-9 [PMID: 8640166]
  3. Blood Adv. 2021 Dec 14;5(23):5140-5149 [PMID: 34581754]
  4. Eur J Haematol. 2022 Jan;108(1):61-72 [PMID: 34606661]
  5. Biol Blood Marrow Transplant. 2020 Jul;26(7):1312-1317 [PMID: 32283185]
  6. Biol Blood Marrow Transplant. 2020 Jul;26(7):e161-e166 [PMID: 32389803]
  7. Biol Blood Marrow Transplant. 2007 Oct;13(10):1233-43 [PMID: 17889361]
  8. Front Immunol. 2022 Sep 20;13:937900 [PMID: 36203566]
  9. Transplant Cell Ther. 2021 Aug;27(8):664.e1-664.e6 [PMID: 33964514]
  10. Bone Marrow Transplant. 2013 Mar;48(3):452-8 [PMID: 23208313]
  11. Cytotherapy. 2021 Jul;23(7):635-640 [PMID: 33423867]
  12. Bone Marrow Transplant. 2008 Jul;42(2):121-8 [PMID: 18391988]
  13. Transpl Infect Dis. 2015 Feb;17(1):56-65 [PMID: 25580541]
  14. Bone Marrow Transplant. 1995 Apr;15(4):569-72 [PMID: 7655383]
  15. Bone Marrow Transplant. 2021 Oct;56(10):2489-2496 [PMID: 34127808]
  16. Transfus Apher Sci. 2020 Aug;59(4):102742 [PMID: 32171686]
  17. Br J Haematol. 1997 Feb;96(2):382-6 [PMID: 9029030]
  18. Am J Hematol. 2021 Feb 1;96(2):179-187 [PMID: 33108034]
  19. Eur J Haematol. 2013 Nov;91(5):448-55 [PMID: 23710624]
  20. Bone Marrow Transplant. 2013 Feb;48(2):243-8 [PMID: 22732701]
  21. Bone Marrow Transplant. 1993 Feb;11(2):125-31 [PMID: 8435661]
  22. Transplant Cell Ther. 2021 Jun;27(6):507-516 [PMID: 33865804]

MeSH Term

Bone Marrow
COVID-19
Graft vs Host Disease
Humans
Japan
Pandemics
Peripheral Blood Stem Cell Transplantation
Retrospective Studies
United States
Journal Article

Word Cloud

Created with Highcharts 10.0.0cryopreservationtransplantationgraftsengraftmentCOVID-19cryopreservedBMTPBSCTneutrophilBMstemcellPBSCCryopreservationMarrowpandemicdonorgraftmaymarrowbloodstudydataunrelatedBMTsPBSCTsincludingrecipients432associateddelayedP = TransplantationBonePeripheralJapanDonorProgramfrequentlyensureavailablestartingconditioningregimenHoweverconflictingreportseffectoutcomesAlsoimpactdifferboneperipheralretrospectiveanalyzedclinicaln = 235n = 118comparedlargecontrolcohortwithout4133720Amongpatients103%5%achieveformerlatterdiedearlymultivariateanalysissignificantlyhazardratio[HR]8295%confidenceinterval[CI]6997023interactionborderlinesignificancesource067Platelet<1%unusedperiodslightdelayplateletacceptableratefailuresensitivereasonableoptionprovidedapheresiscentersadept©2022AmericanSocietyCellularTherapyPublishedElsevierIncEffectUnrelatedBloodStemCellEraPandemic:Update

Similar Articles

Cited By